News

Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, ...
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Why Summit Therapeutics Stock Soared 8% Higher Today
A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...
pharmaphorum2d
Summit climbs on rumour of $15bn AstraZeneca interest
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on PD-1xVEGF bispecific ivonescimab that is estimated to be worth as much as ...
2 Soaring Stocks With More Upside Potential to Buy and Hold
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
The AM Reporter3d
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from HC Wainwright
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued ...
Zacks Investment Research on MSN4d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
Lineage Cell Therapeutics unveils promising Phase I/IIa OpRegen results at CTS 2025
OpRegen is a suspension of embryonic stem cell-derived RPE cells restoring visual function in degenerative retinal ...